The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates.
M. I. Hu
Research Funding - Amgen
R. Gucalp
Consultant or Advisory Role - Eisai
K. L. Insogna
No relevant relationships to disclose
I. Glezerman
Research Funding - Amgen
H. G. Bone
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen; Novartis
A. Jaccard
No relevant relationships to disclose
W. Misiorowski
No relevant relationships to disclose
B. W. Yu
No relevant relationships to disclose
H. Yeh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen